Compare Heron Therapeutics Inc (HRTX) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Live Nation Entertainment, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Live Nation Entertainment, Inc. trades at $171.11 (market cap $39.80B). The key difference: Live Nation Entertainment, Inc. is far larger — about 537.5× Heron Therapeutics Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Live Nation Entertainment, Inc. for 72 Days on average.
| HRTX | LYV | |
|---|---|---|
Market Cap | $74.04M | $39.80B |
Volume | 3,668,095 | 1,162,440 |
Sector | Health | Media |
52-Week High | $1.49 | $188.46 |
52-Week Low | $0.27 | $125.61 |
Typical Hold Time | 35 Days | 72 Days |
Enterprise Value | $180.78M | $42.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Live Nation Entertainment (LYV) trades at $171.34, down 0.26% on the day, with a bullish technical signal and strong analyst support (87% buy ratings). The company reported mixed Q2 2026 earnings with a beat on EPS but faces valuation concerns with a P/E of 117.5 and negative ROE of -116.7%. Recent news highlights strong consumer demand for live events and strategic partnerships, though regulatory scrutiny and insider selling warrant attention.
The outlook remains positive given robust fan attendance and deferred revenue growth, but high valuation and execution risks in a seasonally heavy Q4 present challenges. Wall Street's $208 price target suggests 21% upside, positioning LYV as a growth play on experiential spending trends with balanced risk-reward dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
